Adams Diversified Equity Fund Inc. trimmed its holdings in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) by 22.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,100 shares of the biopharmaceutical company’s stock after selling 14,700 shares during the quarter. Adams Diversified Equity Fund Inc.’s holdings in Sucampo Pharmaceuticals were worth $899,000 at the end of the most recent reporting period.
A number of other hedge funds have also modified their holdings of SCMP. JPMorgan Chase & Co. bought a new position in Sucampo Pharmaceuticals in the 2nd quarter worth approximately $117,000. Wells Fargo & Company MN grew its holdings in Sucampo Pharmaceuticals by 11.3% in the 2nd quarter. Wells Fargo & Company MN now owns 65,571 shares of the biopharmaceutical company’s stock worth $688,000 after buying an additional 6,647 shares in the last quarter. Alliancebernstein L.P. grew its holdings in Sucampo Pharmaceuticals by 30.7% in the 2nd quarter. Alliancebernstein L.P. now owns 38,362 shares of the biopharmaceutical company’s stock worth $403,000 after buying an additional 9,000 shares in the last quarter. Teachers Advisors LLC grew its holdings in Sucampo Pharmaceuticals by 2.9% in the 2nd quarter. Teachers Advisors LLC now owns 68,499 shares of the biopharmaceutical company’s stock worth $719,000 after buying an additional 1,953 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its holdings in Sucampo Pharmaceuticals by 1.3% in the 2nd quarter. Ameriprise Financial Inc. now owns 131,790 shares of the biopharmaceutical company’s stock worth $1,384,000 after buying an additional 1,690 shares in the last quarter. 67.09% of the stock is owned by institutional investors and hedge funds.
A number of brokerages recently issued reports on SCMP. BidaskClub raised Sucampo Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 12th. Leerink Swann reaffirmed a “market perform” rating and set a $15.00 price target on shares of Sucampo Pharmaceuticals in a research note on Tuesday, January 2nd. Zacks Investment Research lowered Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, February 9th. Nomura initiated coverage on Sucampo Pharmaceuticals in a research note on Monday, December 18th. They set a “buy” rating and a $43.00 price target for the company. Finally, B. Riley increased their price target on Sucampo Pharmaceuticals from $14.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, December 6th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $20.25.
In other news, insider Peter A. Kiener sold 50,000 shares of the firm’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the completion of the sale, the insider now directly owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.13% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Sucampo Pharmaceuticals, Inc. (SCMP) Position Cut by Adams Diversified Equity Fund Inc.” was originally published by Ticker Report and is owned by of Ticker Report. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3227109/sucampo-pharmaceuticals-inc-scmp-position-cut-by-adams-diversified-equity-fund-inc.html.
Sucampo Pharmaceuticals Profile
Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.
Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).
Receive News & Ratings for Sucampo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.